--- title: "Lilly's Oral GLP-1 Reads Out: Founding Endowment Holds 9.7%" type: news slug: lly-orforglipron-trial-readout-lilly-endowment-still-largest-holder canonical_url: https://13finsight.com/news/lly-orforglipron-trial-readout-lilly-endowment-still-largest-holder published_at: 2026-05-13T03:07:18.482Z updated_at: 2026-05-13T03:07:21.349Z author: Alex Rivera author_title: Breaking News Editor author_url: https://13finsight.com/authors/alex-rivera word_count: 984 locale: en source: 13F Insight --- # Lilly's Oral GLP-1 Reads Out: Founding Endowment Holds 9.7% > Eli Lilly's oral GLP-1 candidate orforglipron published fresh maintenance-phase data — patients who stopped weekly obesity injections kept the weight off on the daily pill. The pipeline story is well-covered. What gets less attention: the largest holder of LLY isn't BlackRock or Vanguard. It's a private endowment. Eli Lilly's oral GLP-1 candidate orforglipron published new maintenance-phase data this week, showing that patients who discontinued weekly injectable obesity therapies and switched to the daily pill held onto most of the weight loss over an extended follow-up. For Lilly's pipeline, this is the obvious bull case for the next leg of the GLP-1 franchise: if the maintenance read holds across larger trials, orforglipron becomes a step-down treatment that turns the obesity-drug market from a long-term injection commitment into a sequential injectable-then-pill therapeutic ladder.That story has been covered. What's less covered is the part of the institutional book that matters when a pipeline event like this lands: who actually holds Lilly's $700B-plus market cap, and how that base is structured around an entity that doesn't behave like a normal institutional holder.The largest LLY shareholder isn't an asset managerPer the most recent 13F-reported holdings tracked on our platform, the top five holders of Eli Lilly by dollar value are:RankHolder13F-Reported Value1Lilly Endowment Inc.$84.5B2BlackRock$71.8B3PNC Financial Services$54.9B4Vanguard Capital Management$49.1B5State Street$38.0BLilly Endowment Inc. is the founding-family philanthropic foundation, established in 1937 with shares donated by J.K. Lilly Sr. and his sons. It is not a hedge fund and not a 13F asset manager in the conventional sense — it files because it crosses the reporting threshold for the Lilly position alone. Per the April 20, 2026 Schedule 13G/A on file, the Endowment owns 9.7% of Eli Lilly's outstanding stock, down from 9.8% in its January 2026 amendment. A 10-basis-point trim is the equivalent of small portfolio housekeeping at this scale.The relevance for an event like orforglipron's maintenance-phase readout: the company's single largest shareholder is a holder with a near-permanent time horizon and explicit non-economic objectives. Lilly Endowment is required to make charitable distributions roughly equal to 5% of its assets each year, but it has historically funded those distributions through dividends and selective trims rather than meaningful reductions in the underlying Lilly position. The 9.8% → 9.7% sequence is consistent with that pattern.The PNC oddityThe other unusual top-five holder is PNC Financial Services at $54.9 billion. PNC is here for a historical reason rather than an asset-management thesis: the bank's predecessor entities had a long-standing trust relationship with Lilly family vehicles, and a meaningful chunk of the company's Lilly position is held in fiduciary accounts on behalf of Lilly family beneficiaries. PNC's reported position size moves with the underlying share price, not with PNC's active investment decisions.If you strip out Lilly Endowment, PNC's family-trust position, and the index complexes (BlackRock, Vanguard, State Street, Geode), what's left as actively managed Lilly exposure narrows quickly: FMR (Fidelity) at $27.6B, Capital Research Global Investors at $26.4B, Capital World Investors at $16.1B, Wellington Management at $14.4B. These are the names whose Q2 2026 13Fs will be worth reading carefully after orforglipron's readout — they're the holders whose marginal flow is most likely to move on positive pipeline news.The 13G tape: Vanguard reshuffle, Endowment trimRecent 13G/A activity on LLY:2026-05-01: Vanguard Capital Management fresh SC 13G at 6.48%.2026-04-20: Lilly Endowment 13G/A at 9.7% (down from 9.8% in January 2026).2026-03-26: Vanguard Group 13G/A exit at 0.00%.2025-10-30: Vanguard Group prior 13G/A at 8.55%.The Vanguard sequence is the same internal reporting-entity transfer pattern visible across PYPL, ROKU, SCHW, NET, and most other large-caps in the 2026 cycle — see our guide to sequential 13G filings for the underlying mechanic. The 8.55% → 0% → 6.48% sequence is a Vanguard internal pool transfer, not a meaningful position change.The Endowment's 10-basis-point trim is the only directional move on the recent 13G docket. At Lilly's roughly $700B market cap, a 0.1% trim is approximately $700M in shares — small in absolute dollar terms relative to the Endowment's $84.5B position, but it does mark the second consecutive amendment trim from this holder.Why the structure matters for pipeline eventsWhen a pipeline readout lands, the question for the stock is who is positioned to add into the move and who is positioned to sell into it. The structural pieces of Lilly's holder base behave differently:Lilly Endowment: won't add (concentration is already extreme), unlikely to trim aggressively. Functionally indifferent to a single readout.PNC family-trust holdings: won't add or sell on this news. The trust mandate is the driver, not the pipeline.Index complexes (BlackRock, Vanguard, State Street, Geode): will adjust position size only to the extent that Lilly's weight in their indexes changes — i.e., when the market cap moves, the mechanical position adjusts. Not a directional buyer or seller.Active growth and quality managers (FMR, Capital Research, Capital World, Wellington): these are the books that read pipeline data, model the long-term obesity-drug TAM, and adjust exposure accordingly. Their Q2 2026 13Fs will be the read worth waiting for.For an investor watching the tape: the Lilly Endowment's 9.7% block effectively acts as a long-duration owner who is unlikely to provide supply at any reasonable price. PNC's family-trust exposure adds another layer of structural patience. The result is that LLY's true free-float — shares actually available to be bid for or against by active managers — is materially lower than the headline market cap suggests. That structural tightness amplifies the price reaction to events like pipeline readouts in both directions.What to watchThe next Endowment 13G/A: if the trim accelerates beyond a 10-basis-point pace, that's the more meaningful institutional signal than any active-manager move.Q2 2026 13Fs (due August 14): Capital Research, Capital World, FMR, and Wellington's adjustments will tell you whether active managers underwrote the orforglipron readout as the franchise-extending story or treated it as already in price.Form 4 activity from Lilly insiders: the platform shows no recent material insider transactions ahead of the readout window, which is consistent with the company's reporting-window blackout calendar.Orforglipron's readout is what gets written about. The fact that Lilly's largest single holder is a foundation that doesn't trade on it — and that the second-largest active-conviction holder is a family trust — is what shapes how the stock actually behaves into the data. ## FAQ ### Who is the biggest shareholder of Eli Lilly? The largest holder of Eli Lilly is Lilly Endowment Inc., the founding-family philanthropic foundation established in 1937. Per its April 20, 2026 Schedule 13G/A, it owns 9.7% of LLY shares, down from 9.8% in January 2026. The position is worth approximately $84.5 billion. ### What is orforglipron? Orforglipron is an oral once-daily GLP-1 receptor agonist being developed by Eli Lilly as a treatment for obesity and Type 2 diabetes. Recent maintenance-phase data showed patients who stopped weekly injectable GLP-1 therapy and switched to orforglipron retained most of their weight loss over extended follow-up. ### Why does PNC Financial Services own so much Eli Lilly stock? PNC's $54.9 billion LLY position reflects long-standing fiduciary relationships with Lilly family trusts and estate vehicles, not active investment decisions by PNC's asset management business. The position moves with the underlying share price rather than with PNC's discretionary allocation. ### How much of Eli Lilly is owned by active managers versus passive funds? After excluding Lilly Endowment's 9.7% block, PNC's fiduciary holdings, and the index complexes (BlackRock, Vanguard, State Street, Geode), the largest active managers in LLY are FMR ($27.6B), Capital Research Global Investors ($26.4B), Capital World Investors ($16.1B), and Wellington Management ($14.4B). --- Source: 13F Insight — https://13finsight.com/news/lly-orforglipron-trial-readout-lilly-endowment-still-largest-holder Author: Alex Rivera — https://13finsight.com/authors/alex-rivera Last updated: 2026-05-13T03:07:21.349Z